구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lentiviral Gene Transfer (Lentiviral Gene Transfer) National Human Genome Research Ins…·Adenosine Deaminase Deficiency 55 trials |
|---|---|
Overview Program | Lentiviral Gene Transfer |
Overview Company | National Human Genome Research Institute (NHGRI) |
Overview Modality | CGT |
Overview Target | Adenosine Deaminase Deficiency |
Overview Indication | Adenosine Deaminase Deficiency; ADA-SCID |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentiviral gene transfer to downregulate orexin expression in male and female young rats t |
MoA Mechanism | targeting, which can enhance tumor-antigen |
MoA Biomarker | PD-1/PD-L1 signaling low |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia, infections, eczema, autoimmunity, and malignant disease |
Clinical Safety signal | thrombocytopenia, infections, eczema, autoimmunity, and malignant disease |
Clinical Result source | ClinicalTrials.gov NCT01380990 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT01380990 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lentiviral Gene Transfer (Lentiviral Gene Transfer) National Human Genome Research Ins…·Adenosine Deaminase Deficiency 55 trials |
|---|---|
Overview Program | Lentiviral Gene Transfer |
Overview Company | National Human Genome Research Institute (NHGRI) |
Overview Modality | CGT |
Overview Target | Adenosine Deaminase Deficiency |
Overview Indication | Adenosine Deaminase Deficiency; ADA-SCID |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentiviral gene transfer to downregulate orexin expression in male and female young rats t |
MoA Mechanism | targeting, which can enhance tumor-antigen |
MoA Biomarker | PD-1/PD-L1 signaling low |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia, infections, eczema, autoimmunity, and malignant disease |
Clinical Safety signal | thrombocytopenia, infections, eczema, autoimmunity, and malignant disease |
Clinical Result source | ClinicalTrials.gov NCT01380990 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT01380990 |
추천 비교
추천 비교